Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The research will test innovative technology that harnesses the body’s intrinsic immune system to transform the treatment of cancer and autoimmune diseases.

© richardlewisohn.co.uk

Dr Michael Dustin has entered into a research collaboration agreement with Cue Biopharma, Inc. a clinical-stage biopharmaceutical company that is engineering a novel class of injectable biological treatments designed to selectively seek out and modify targeted T cells within the body.

Viewed as an exciting next step towards the targeted treatment of both solid and blood cancers, the research collaboration aims to determine the interaction of IL-2, a molecule known to stimulate the immune system with Cue Biopharma's CUE-100 series Immuno-STAT™ (Selective Targeting and Alteration of T cells) Biologics.

"We look forward to working with Cue Biopharma on this innovative and promising new technology," said Michael. "We have long appreciated the effects of IL-2 on the immunological synapse, and this research collaboration will allow us to systematically study effects of natural IL-2 and the engineered Immuno-STAT to define potential features of the Immuno-STAT platform that may be driving the selective and preferential modulation of T cells."

Saso Cemerski, senior director of immuno-oncology discovery and translational immunology at Cue Biopharma said: "Dr. Dustin, the scientific pioneer and founder of the T cell immune synapse field has made seminal observations contributing toward our understanding of the biophysical interactions and signaling pathways that underscore immune cell activation, including the mechanistic underpinnings of T cell recognition of antigens. Our strategic collaboration will exploit the state-of-the art technologies pioneered by Dr. Dustin's lab to elucidate the immune synapse interactions of our IL-2-based CUE-100 series that ultimately result in selective and specific activation of tumor-antigen-specific T cells."

Similar stories

Oxford-Bristol Myers Squibb Fellowships awarded to NDORMS researchers

Six researchers from the Botnar Research Centre and the Kennedy Institute of Rheumatology at NDORMS have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme, providing them an opportunity to gain exposure to the field of commercial drug discovery and development.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

NDORMS researchers join new multidisciplinary oncology research project

OPTIMA aims to improve treatment for patients with prostate, breast and lung cancer through artificial intelligence

Novo Nordisk Postdoctoral Research Fellowship awarded to Inhye Park

Inhye Park has been awarded a Novo Nordisk Postdoctoral Research Fellowship to research the biology of resident vascular macrophages in atherosclerosis.

Professor David Beard awarded BOA Honorary Fellowship

Professor of Musculoskeletal and Surgical Science, David Beard, has been awarded an Honorary Fellowship by the British Orthopaedic Association.

Farewell to Angela, NDORMS Head of Administration

Angela Truesdale, who has retired from her role as Head of Administration at NDORMS will be fondly missed by all her colleagues and across the division.